EdiGene
PrivateLast Round
Series B
Extension
Apr 21, 2021
Total Funding Raised
$160M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
EdiGene operates in Healthcare & Life Sciences and is based in Beijing. Its latest recorded funding round was a Series B Extension round in April 2021.
EdiGene is a biotechnology company that develops genome editing technologies to accelerate drug discovery and create novel therapeutics for genetic diseases and cancers.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
EdiGene Comparables
Compare EdiGene with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| BRL Medicine Inc. | 87% | |
| Shanghai Bendao Gene Technology | 84% | |
| AIRNA | 80% |
For institutional investors. Book with your work email.
EdiGene Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Apr 21, 2021 | ||||
| Series B | Oct 13, 2020 | ||||
| Series A Extension | Sep 16, 2019 | ||||
| Series A Extension | Feb 4, 2019 | ||||
| VC Round | Aug 24, 2018 |
For institutional investors. Book with your work email.
EdiGene Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Alwin Capital | Series B Extension, Series B |
| BioTrack Capital | Series B Extension |
| BGI Co-Win | VC Round |
| Loyal Valley Capital | Series B Extension |
| IDG Capital | VC Round, Series B Extension, Series B, Series A Extension, Series A |
| Sincere Capital | VC Round, Series B |
| WI Harper Group | Series A, VC Round |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 19, 2026
Open roles increased to 148, 3.4x the trailing average.
- Oct 12, 2026
Open roles increased to 100, 2.17x headcount.
For institutional investors. Book with your work email.
EdiGene Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about EdiGene's valuation, stock price, and market status.
Is EdiGene a public or private company?
EdiGene is a private company.
What is the current stock price of EdiGene?
EdiGene is a private company, so its shares have no public market price. Caplight tracks EdiGene's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is EdiGene worth (valuation)?
Valuation information for EdiGene is not publicly available.
Can I buy EdiGene stock?
EdiGene shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was EdiGene's last funding round?
EdiGene's most recent funding round was Series B Extension on April 21, 2021.
Who are the main investors in EdiGene?
Key investors in EdiGene include Loyal Valley Capital, IDG Capital, 3H Health Investment, Lilly Asia Ventures, Lilly Asia Ventures.
Will EdiGene IPO soon?
No public IPO plans have been announced for EdiGene.
How can I track EdiGene secondary market activity?
Caplight tracks bids, offers, and trades in EdiGene's shares on secondary markets.